Aptevo Therapeutics Inc.APVONASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +3589.74% | +12095.33% | +7757.37% | +15418.35% | +28304.88% |
| Weighted Average Shares Diluted Growth | +3589.74% | +12095.33% | +7757.37% | +15418.35% | +28304.88% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -44.17% | -37.24% | -52.68% | +4.71% | +78.24% |
| Book Value per Share Growth | -99.19% | -99.68% | +0.00% | -99.06% | -98.61% |
| Debt Growth | -13.36% | -14.23% | -15.19% | -16.24% | -17.39% |
| R&D Expense Growth | -20.17% | +8.05% | -0.36% | -8.65% | +30.33% |
| SG&A Expenses Growth | -21.09% | -10.42% | -11.88% | +21.71% | +69.00% |